Selecta Biosciences to Participate at the 20th Annual Needham Healthcare Conference
April 05, 2021 08:00 ET
|
Selecta Biosciences, Inc.
WATERTOWN, Mass., April 05, 2021 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic...
Selecta Biosciences Reports Recent Business Highlights and Fourth Quarter and Full Year 2020 Financial Results
March 11, 2021 08:00 ET
|
Selecta Biosciences, Inc.
- First-in-human dose-escalation study to evaluate ability of ImmTOR™ to mitigate immunogenicity of AAV capsid initiated with initial data expected in the fourth quarter of 2021 - - Methylmalonic...
Selecta Biosciences to Host Conference Call and Webcast to Discuss Fourth Quarter and Full-Year 2020 Financial Results and Recent Operational Highlights
March 04, 2021 08:00 ET
|
Selecta Biosciences, Inc.
WATERTOWN, Mass., March 04, 2021 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic...
Selecta Biosciences to Participate in the H.C. Wainwright Global Life Sciences Conference
March 01, 2021 08:00 ET
|
Selecta Biosciences, Inc.
WATERTOWN, Mass., March 01, 2021 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic...
Selecta Biosciences Announces Science Advances Publication Highlighting Potential Potency and Durability Benefits of ImmTOR™ in Gene Therapy
February 24, 2021 16:15 ET
|
Selecta Biosciences, Inc.
- Data demonstrate that ImmTOR has the potential to enhance transgene expression in the liver at initial dose of AAV vector - - ImmTOR shown to increase hepatic vector copy numbers and transgene mRNA...
Selecta Biosciences and AskBio Initiate First-in-Human Dose-Escalation Study to Evaluate ImmTOR™ in Gene Therapy
February 17, 2021 08:00 ET
|
Selecta Biosciences, Inc.
– Clinical trial commences in healthy adult volunteers to determine appropriate dose of ImmTOR to mitigate formation of antibodies to AAV capsids used in gene therapy – WATERTOWN, Mass. and RESEARCH...
Selecta Biosciences to Present at the SVB Leerink 10th Annual Global Healthcare Conference
February 16, 2021 08:00 ET
|
Selecta Biosciences, Inc.
WATERTOWN, Mass., Feb. 16, 2021 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic...
Selecta Biosciences Announces Data in Non-Human Primates, Further Validating Multiple Potential Benefits of the ImmTORTM Platform in Gene Therapy
January 06, 2021 08:00 ET
|
Selecta Biosciences, Inc.
- Co-administration of AAV8 and ImmTOR shows first dose benefit of higher and more durable transgene expression, in addition to mitigating the formation of neutralizing antibodies, compared to AAV8...
Selecta Biosciences to Participate in the H.C. Wainwright BioConnect 2021 Conference
January 04, 2021 08:00 ET
|
Selecta Biosciences, Inc.
WATERTOWN, Mass., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic...